Menu Search
Equities

Philogen SpA

  • Add to watchlist
  • Add to portfolio
  • Add an alert
78Q:STU

Philogen SpA

Actions
  • Price (EUR)20.70
  • Today's Change-0.70 / -3.27%
  • Shares traded0.00
  • 1 Year change+9.23%
  • Beta0.2258
Data delayed at least 15 minutes, as of Feb 06 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Philogen SpA is an Italy-based company operating in the biotechnology sector. The Company develops products and technologies for the diagnosis and therapy of serious human diseases. It focuses mainly on discovering and developing targeted anti-cancer drugs, using high-affinity ligands for tumor markers. These ligands are identified through Antibody Phage Display Libraries and DNA-Encoded Chemical Libraries technologies. The Company’s products primarily address applications in the oncology field, the targeting approach is also potentially applicable to other diseases, such as certain chronic inflammatory diseases. It has four anti-cancer antibody derivatives in clinical studies, one of which has completed a Phase III trial. The Company is active in the Discovery Unit through its subsidiary Philochem AG.

  • Revenue in EUR (TTM)78.72m
  • Net income in EUR45.91m
  • Incorporated--
  • Employees193.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.